GLOBAL INITIATIVE FOR ASTHMA

Board of Directors (2012)

Mark FitzGerald, M.D., Canada, Chair
Eric D. Bateman, M.D., South Africa
Louis-Philippe Boulet, M.D., Canada
Alvaro Cruz, M.D., Brazil
Tari Haahtela, M.D., Finland
Mark Levy, M.D., United Kingdom
Paul O’Byrne, M.D., Canada
Ken Ohta, M.D., Japan
Pierluigi Paggario, M.D., Italy
Soren Pedersen, M.D., Denmark
Manuel Soto-Quiroz, M.D., Costa Rica
Gary Wong, M.D., Hong Kong ROC

GINA Assembly (2012)

Louis-Philippe Boulet, MD, Canada, Chair
GINA Assembly members from 45 countries (names are listed on website: www.ginasthma.org)
# TABLE OF CONTENTS

**PREFACE** .................................................................................................................. 3

**WHAT IS KNOWN ABOUT ASTHMA?** .................................................................. 5

**DIAGNOSING ASTHMA** ......................................................................................... 7

  Figure 1. Is it Asthma? .................................................................................................. 7

**CLASSIFICATION OF ASTHMA BY LEVEL OF CONTROL** .......................... 9

  Figure 2. Levels of Asthma Control ............................................................................ 9

**FOUR COMPONENTS OF ASTHMA CARE** ..................................................... 10

  **Component 1. Develop Patient/Doctor Partnership** ........................................ 10

  Figure 3. Example of Contents of an Action Plan to Maintain Asthma Control .... 11

  **Component 2. Identify and Reduce Exposure to Risk Factors** ...................... 12

  Figure 4. Strategies for Avoiding Common Allergens and Pollutants .......... 12

  **Component 3. Assess, Treat, and Monitor Asthma** ...................................... 13

  Figure 5. Management Approach Based on Control ........................................ 15

  Figure 6. Estimated Equipotent Doses of Inhaled Glucocorticosteroids ......... 16

  Figure 7. Questions for Monitoring Asthma care .............................................. 18

  **Component 4. Manage Exacerbations** ......................................................... 19

  Figure 8. Severity of Asthma Exacerbations .................................................... 22

**SPECIAL CONSIDERATIONS IN MANAGING ASTHMA** ............................. 23

  **Appendix A: Glossary of Asthma Medications - Controllers** ................... 24

  **Appendix B: Combination Medications for Asthma** ................................... 25

  **Appendix C: Glossary of Asthma Medications - Relievers** ...................... 26
PREFACE

Asthma is a major cause of chronic morbidity and mortality throughout the world and there is evidence that its prevalence has increased considerably over the past 20 years, especially in children. The Global Initiative for Asthma was created to increase awareness of asthma among health professionals, public health authorities, and the general public, and to improve prevention and management through a concerted worldwide effort. The Initiative prepares scientific reports on asthma, encourages dissemination and implementation of the recommendations, and promotes international collaboration on asthma research.

The Global Initiative for Asthma offers a framework to achieve and maintain asthma control for most patients that can be adapted to local health care systems and resources. Educational tools, such as laminated cards, or computer-based learning programs can be prepared that are tailored to these systems and resources.

The Global Initiative for Asthma program publications include:

- **What You and Your Family Can Do About Asthma**. An information booklet for patients and their families.

Publications are available from www.ginasthma.org.

This Pocket Guide has been developed from the Global Strategy for Asthma Management and Prevention (Updated 2012). Technical discussions of asthma, evidence levels, and specific citations from the scientific literature are included in that source document.
Acknowledgements:

Grateful acknowledgement is given for unrestricted educational grants from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi Group, CIPLA, GlaxoSmithKline, Merck Sharp & Dohme, Novartis, Quintiles and Takeda. The generous contributions of these companies assured that the GINA Committees could meet together and publications could be printed for wide distribution. However, the GINA Committee participants are solely responsible for the statements and conclusions in the publications.
WHAT IS KNOWN ABOUT ASTHMA?

Unfortunately...asthma is one of the most common chronic diseases, with an estimated 300 million individuals affected worldwide. Its prevalence is increasing, especially among children.

Fortunately...asthma can be effectively treated and most patients can achieve good control of their disease. When asthma is under control patients can:

- Avoid troublesome symptoms night and day
- Use little or no reliever medication
- Have productive, physically active lives
- Have (near) normal lung function
- Avoid serious attacks

- Asthma causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning.

- Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, and increased inflammation) when airways are exposed to various risk factors.

- Common risk factors for asthma symptoms include exposure to allergens (such as those from house dust mites, animals with fur, cockroaches, pollens, and molds), occupational irritants, tobacco smoke, respiratory (viral) infections, exercise, strong emotional expressions, chemical irritants, and drugs (such as aspirin and beta blockers).

- A stepwise approach to pharmacologic treatment to achieve and maintain control of asthma should take into account the safety of treatment, potential for adverse effects, and the cost of treatment required to achieve control.

- Asthma attacks (or exacerbations) are episodic, but airway inflammation is chronically present.
• For many patients, **controller** medication must be taken daily to prevent symptoms, improve lung function, and prevent attacks. **Reliever** medications may occasionally be required to treat acute symptoms such as wheezing, chest tightness, and cough.

• To reach and maintain asthma control requires the development of a **partnership** between the person with asthma and his or her health care team.

• Asthma is not a cause for shame. Olympic athletes, famous leaders, other celebrities, and ordinary people live **successful lives** with asthma.
Asthma can often be diagnosed on the basis of a patient’s symptoms and medical history (Figure 1).

**Measurements of lung function** provide an assessment of the severity, repairability, and variability of airflow limitation, and help confirm the diagnosis of asthma.

**Spirometry** is the preferred method of measuring airflow limitation and its reversibility to establish a diagnosis of asthma.

- An increase in FEV₁ of ≥ 12% and ≥ 200 ml after administration of a bronchodilator indicates reversible airflow limitation consistent with asthma. (However, most asthma patients will not exhibit reversibility at each assessment, and repeated testing is advised.)

---

**Figure 1. Is it Asthma?**

Presence of any of these signs and symptoms should increase the suspicion of asthma:

- Wheezing high-pitched whistling sounds when breathing out—especially in children. (A normal chest examination does not exclude asthma.)
- History of any of the following:
  - Cough, worse particularly at night
  - Recurrent wheeze
  - Recurrent difficult breathing
  - Recurrent chest tightness
- Symptoms occur or worsen at night, awakening the patient.
- Symptoms occur or worsen in a seasonal pattern.
- The patient also has eczema, hay fever, or a family history of asthma or atopic diseases.
- Symptoms occur or worsen in the presence of:
  - Animals with fur
  - Aerosol chemicals
  - Changes in temperature
  - Domestic dust mites
  - Drugs (aspirin, beta-blockers)
  - Exercise
  - Pollen
  - Respiratory (viral) infections
  - Smoke
  - Strong emotional expression
- Symptoms respond to anti-asthma therapy
- Patients colds "go to the chest" or take more than 10 days to clear up
Peak expiratory flow (PEF) measurements can be an important aid in both diagnosis and monitoring of asthma.

- PEF measurements are ideally compared to the patient’s own previous best measurements using his/her own peak flow meter.
- An improvement of 60 L/min (or ≥ 20% of the pre-bronchodilator PEF) after inhalation of a bronchodilator, or diurnal variation in PEF of more than 20% (with twice-daily readings, more than 10%), suggests a diagnosis of asthma.

Additional diagnostic tests:

- For patients with symptoms consistent with asthma, but normal lung function, measurements of airway responsiveness to methacholine and histamine, an indirect challenge test such as inhaled mannitol, or exercise challenge may help establish a diagnosis of asthma.
- Skin tests with allergens or measurement of specific IgE in serum: The presence of allergies increases the probability of a diagnosis of asthma, and can help to identify risk factors that cause asthma symptoms in individual patients.

Diagnostic Challenges

- **Cough-variant asthma.** Some patients with asthma have chronic cough (frequently occurring at night) as their principal, if not only, symptom. For these patients, documentation of lung function variability and airway hyperresponsiveness are particularly important.
- **Exercise-induced bronchoconstriction.** Physical activity is an important cause of asthma symptoms for most asthma patients, and for some (including many children) it is the only cause. Exercise testing with an 8-minute running protocol can establish a firm diagnosis of asthma.
- **Children 5 Years and Younger.** Not all young children who wheeze have asthma. In this age group, the diagnosis of asthma must be based largely on clinical judgment, and should be periodically reviewed as the child grows (see the *GINA Pocket Guide for Asthma Management and Prevention in Children 5 Years and Younger* for further details).
- **Asthma in the elderly.** Diagnosis and treatment of asthma in the elderly are complicated by several factors, including poor perception of symptoms, acceptance of dyspnea as being “normal” for old age, and reduced expectations of mobility and activity. Distinguishing asthma from COPD is particularly difficult, and may require a trial of treatment.
- **Occupational asthma.** Asthma acquired in the workplace is a diagnosis that is frequently missed. The diagnosis requires a defined history of occupational exposure to sensitizing agents; an absence of asthma symptoms before beginning employment; and a documented relationship between symptoms and the workplace (improvement in symptoms away from work and worsening of symptoms upon returning to work).
CLASSIFICATION OF ASTHMA BY LEVEL OF CONTROL

The goal of asthma care is to achieve and maintain control of the clinical manifestations of the disease for prolonged periods. When asthma is controlled, patients can prevent most attacks, avoid troublesome symptoms day and night, and keep physically active.

The assessment of asthma control should include control of the clinical manifestations and control of the expected future risk to the patient such as exacerbations, accelerated decline in lung function, and side-effects of treatment. In general, the achievement of good clinical control of asthma leads to reduced risk of exacerbations.

Figure 2 describes the clinical characteristics of controlled, partly controlled, and uncontrolled asthma.

Example of validated measures for assessing clinical control of asthma include:
- Asthma Control Test (ACT): www.asthmacontrol.com
- Childhood Asthma Control Test (C-Act)
- Asthma Control Questionnaire (ACQ): www.qoltech.co.uk/Asthma1.htm
- Asthma Therapy Assessment Questionnaire (ATAQ): www.ataqinstrument.com
- Asthma Control Scoring System
FOUR COMPONENTS OF ASTHMA CARE

Four interrelated components of therapy are required to achieve and maintain control of asthma:

**Component 1.** Develop patient/doctor partnership
**Component 2.** Identify and reduce exposure to risk factors
**Component 3.** Assess, treat, and monitor asthma
**Component 4.** Manage asthma exacerbations

**Component 1: Develop Patient/Doctor Partnership**

The effective management of asthma requires the development of a partnership between the person with asthma and his or her health care team.

With your help, and the help of others on the health care team, patients can learn to:

- Avoid risk factors
- Take medications correctly
- Understand the difference between "controller" and "reliever" medications
- Monitor their status using symptoms and, if relevant, PEF
- Recognize signs that asthma is worsening and take action
- Seek medical advice as appropriate

Education should be an integral part of all interactions between health care professionals and patients. Using a variety of methods—such as discussions (with a physician, nurse, outreach worker, counselor, or educator), demonstrations, written materials, group classes, video or audio tapes, dramas, and patient support groups—helps reinforce educational messages.

Working together, you and your patient should prepare a written personal asthma action plan that is medically appropriate and practical. A sample asthma plan is shown in Figure 3.

Additional written asthma action plans can be found on several websites, including:

- [www.asthma.org.uk](http://www.asthma.org.uk)
- [www.nhlbisupport.com/asthma/index.html](http://www.nhlbisupport.com/asthma/index.html)
- [www.asthmanz.co.nz](http://www.asthmanz.co.nz)
### Your Regular Treatment:
1. Each day take __________________________  
2. Before exercise, take _____________________  

### WHEN TO INCREASE TREATMENT

**Assess your level of Asthma Control**

In the past week have you had:

- Daytime asthma symptoms more than 2 times?  
  - No  
  - Yes  
- Activity or exercise limited by asthma?  
  - No  
  - Yes  
- Walking at night because of asthma?  
  - No  
  - Yes  
- The need to use your (rescue medication) more than 2 times?  
  - No  
  - Yes  
- If you are monitoring peak flow, peak flow less than ______?  
  - No  
  - Yes

If you answered YES to three or more of these questions, your asthma is uncontrolled and you may need to step up your treatment.

### HOW TO INCREASE TREATMENT

**STEP UP** your treatment as follows and assess improvement every day:

- ___________________________ [Write in next treatment step here]
- Maintain this treatment for ________________________ days [specify number]

### WHEN TO CALL THE DOCTOR/CLINIC.

Call your doctor/clinic: ________________________ [provide phone numbers]
If you don't respond in ________________ days [specify number]

[optional lines for additional instruction]

### EMERGENCY/SEVERE LOSS OF CONTROL

- ✓ If you have severe shortness of breath, and can only speak in short sentences,  
- ✓ If you having a severe attack of asthma and are frightened,  
- ✓ If you need your reliever medication more than every 4 hours and are not improving.

1. Take 2 to 4 puffs ____________________ [reliever medication].  
2. Use ______ mg of __________________________ (oral glucocorticosteroid).  
3. Seek medical help: Go to ______________________________  
   - Address: __________________________  
   - Phone: ________________________________  
4. Continue to use your ___________________________ [reliever medication] until you are able to get medical help.
Component 2: Identify and Reduce Exposure to Risk Factors

To improve control of asthma and reduce medication needs, patients should take steps to avoid the risk factors that cause their asthma symptoms (Figure 4). However, many asthma patients react to multiple factors that are ubiquitous in the environment, and avoiding some of these factors completely is nearly impossible. Thus, medications to maintain asthma control have an important role because patients are often less sensitive to these risk factors when their asthma is under control.

Physical activity is a common cause of asthma symptoms but patients should not avoid exercise. Symptoms can be prevented by taking a rapid-acting inhaled β₂-agonist before strenuous exercise (a leukotriene modifier or cromone are alternatives).

Patients with moderate to severe asthma should be advised to receive an influenza vaccination every year, or at least when vaccination of the general population is advised. Inactivated influenza vaccines are safe for adults and children over age 3.

### Figure 4. Strategies for Avoiding Common Allergens and Pollutants

Avoidance measures that improve control of asthma and reduce medication needs:

- **Tobacco smoke:** Stay away from tobacco smoke. Patients and parents should not smoke.
- **Drugs, foods, and additives:** Avoid if they are known to cause symptoms.
- **Occupational sensitizers:** Reduce or, preferably, avoid exposure to these agents

Reasonable avoidance measures that can be recommended but have not been shown to have clinical benefit

- **House dust mites:** Wash bed linens and blankets weekly in hot water and dry in a hot dryer or sun. Encase pillows and mattresses in air-tight covers. Replace carpets with hard flooring, especially in sleeping rooms. (If possible, use vacuum cleaner with filters. Use acaricides or tannic acid to kill mites—but make sure the patient is not at home when the treatment occurs.
- **Animals with fur:** Use air filters. (Remove animals from the home, or at least from the sleeping area. Wash the pet.)
- **Cockroaches:** Clean home thoroughly and often. Use pesticide spray—but make sure the patient is not at home when spraying occurs.
- **Outdoor pollens and mold:** Close windows and doors and remain indoors when pollen and mold counts are highest.
- **Indoor mold:** Reduce dampness in the home; clean any damp areas frequently
Component 3: Assess, Treat and Monitor Asthma

The goal of asthma treatment—to achieve and maintain clinical control—can be reached in most patients through a continuous cycle that involves

- Assessing Asthma Control
- Treating to Achieve Control
- Monitoring to Maintain Control

Assessing Asthma Control

Each patient should be assessed to establish his or her current treatment regimen, adherence to the current regimen, and level of asthma control. A simplified scheme for recognizing controlled, partly controlled, and uncontrolled asthma is provided in Figure 2.

Treating to Achieve Control

Each patient is assigned to one of five treatment “steps.” Figure 5 details the treatments at each step for adults and children age 5 and over.

At each treatment step, reliever medication should be provided for quick relief of symptoms as needed. (However, be aware of how much reliever medication the patient is using—regular or increased use indicates that asthma is not well controlled.)

At Steps 2 through 5, patients also require one or more regular controller medications, which keep symptoms and attacks from starting. Inhaled glucocorticosteroids (Figure 6) are the most effective controller medications currently available.

For most patients newly diagnosed with asthma or not yet on medication, treatment should be started at Step 2 (or if the patient is very symptomatic, at Step 3). If asthma is not controlled on the current treatment regimen, treatment should be stepped up until control is achieved.

Patients who do not reach an acceptable level of control at Step 4 can be considered to have difficult-to-treat asthma. In these patients, a compromise may need to be reached focusing on achieving the best level of control feasible—with as little disruption of activities and as few daily symptoms as possible—while minimizing the potential for adverse effects from treatment. Referral to an asthma specialist may be helpful.
A variety of controller (Appendix A and Appendix B) and reliever (Appendix C) medications for asthma are available. The recommended treatments are guidelines only. Local resources and individual patient circumstances should determine the specific therapy prescribed for each patient.

**Inhaled medications** are preferred because they deliver drugs directly to the airways where they are needed, resulting in potent therapeutic effects with fewer systemic side effects. Inhaled medications for asthma are available as pressurized metered-dose inhalers (pMDIs), breath-actuated MDIs, dry powder inhalers (DPIs), and nebulizers. Spacer (or valved holding-chamber) devices make inhalers easier to use and reduce systemic absorption and side effects of inhaled glucocorticosteroids.

Teach patients (and parents) how to use inhaler devices. Different devices need different inhalation techniques.

- Give demonstrations and illustrated instructions.
- Ask patients to show their technique at every visit.
- Information about use of various inhaler devices is found on the GINA Website (www.ginasthma.org).
Figure 5. Management Approach Based on Control Adults and Children Older Than 5 Years

### Treatment Steps

<table>
<thead>
<tr>
<th>Level of Control</th>
<th>Treatment Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controlled</td>
<td>Maintain and find lowest controlling step</td>
</tr>
<tr>
<td>Partly controlled</td>
<td>Consider stepping up to gain control</td>
</tr>
<tr>
<td>Uncontrolled</td>
<td>Step up until controlled</td>
</tr>
<tr>
<td>Exacerbation</td>
<td>Treat as exacerbation</td>
</tr>
</tbody>
</table>

#### Controller options***

<table>
<thead>
<tr>
<th>As needed rapid-acting β2-agonist</th>
<th>As needed rapid-acting β2-agonist</th>
</tr>
</thead>
<tbody>
<tr>
<td>Select one</td>
<td>Select one</td>
</tr>
<tr>
<td>Low-dose inhaled ICS*</td>
<td>Low-dose ICS plus long-acting β2-agonist</td>
</tr>
<tr>
<td>Leukotriene modifier**</td>
<td>Medium-or high-dose ICS plus long-acting β2-agonist</td>
</tr>
<tr>
<td>Low-dose ICS plus leukotriene modifier</td>
<td>Leukotriene modifier</td>
</tr>
<tr>
<td>Low-dose ICS plus sustained release theophylline</td>
<td>Anti-IgE treatment</td>
</tr>
</tbody>
</table>

*ICS = inhaled glucocorticosteroids
** = Receptor antagonist or synthesis inhibitors
*** = Recommended treatment (shaded boxes) based on group mean data. Individual patient needs, preferences, and circumstances (including costs) should be considered.

Alternative reliever treatments include inhaled anticholinergics, short-acting oral β2-agonists, some long-acting β2-agonists, and short-acting theophylline. Regular dosing with short and long-acting β2-agonists is not advised unless accompanied by regular use of an inhaled glucocorticosteroid.

For management of asthma in children 5 years and younger, refer to the Global Strategy for the Diagnosis and Management of Asthma in Children 5 Years and Younger, available at http://www.ginasthma.org.
**Table 6. Estimated Equipotent Daily Doses of Inhaled Glucocorticosteroids for Adults and Children Older than 5 Years †**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Low Dose (µg)†</th>
<th>Medium Daily Dose (µg)†</th>
<th>High Daily Dose (µg)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Beclomethasone dipropionate - CFC</td>
<td>200 - 500</td>
<td>&gt; 500 - 1000</td>
<td>&gt; 1000 - 2000</td>
</tr>
<tr>
<td>Beclomethasone dipropionate - HFA</td>
<td>100 - 250</td>
<td>&gt; 250 - 500</td>
<td>&gt; 500 - 1000</td>
</tr>
<tr>
<td>Budesonide*</td>
<td>200 - 400</td>
<td>&gt; 400 - 800</td>
<td>&gt; 800 - 1600</td>
</tr>
<tr>
<td>Ciclesonide*</td>
<td>80 - 160</td>
<td>&gt; 160 - 320</td>
<td>&gt; 320 - 1280</td>
</tr>
<tr>
<td>Flunisolide</td>
<td>500 - 1000</td>
<td>&gt; 1000 - 2000</td>
<td>&gt; 2000</td>
</tr>
<tr>
<td>Fluticasone propionate</td>
<td>100 - 250</td>
<td>&gt; 250 - 500</td>
<td>&gt; 500 - 1000</td>
</tr>
<tr>
<td>Mometasone furoate*</td>
<td>200</td>
<td>&gt; 400</td>
<td>&gt; 800</td>
</tr>
<tr>
<td>Triamcinolone acetonide</td>
<td>400 - 1000</td>
<td>&gt; 1000 - 2000</td>
<td>&gt; 2000</td>
</tr>
</tbody>
</table>

† Comparisons based on efficacy data.

‡ Patients considered for high daily doses except for short periods should be referred to a specialist for assessment to consider alternative combinations of controllers. Maximum recommended doses are arbitrary but with prolonged use are associated with increased risk of systemic side effects.

* Approved for once-daily dosing in mild patients.

**Notes**

- The most important determinant of appropriate dosing is the clinician’s judgment of the patient’s response to therapy. The clinician must monitor the patient’s response in terms of clinical control and adjust the dose accordingly. Once control of asthma is achieved, the dose of medication should be carefully titrated to the minimum dose required to maintain control, thus reducing the potential for adverse effects.

- Designation of low, medium, and high doses is provided from manufacturers’ recommendations where possible. Clear demonstration of dose response relationships is seldom provided or available. The principle is therefore to establish the minimum effective controlling dose in each patient, as higher doses may not be more effective and are likely to be associated with greater potential for adverse effects.

- As CFC preparations are taken from the market, medication inserts for HFA preparations should be carefully reviewed by the clinician for the equivalent correct dosage.
Monitoring to Maintain Control

Ongoing monitoring is essential to maintain control and establish the lowest step and dose of treatment to minimize cost and maximize safety.

Typically, patients should be seen one to three months after the initial visit, and every three months thereafter. After an exacerbation, follow-up should be offered within two weeks to one month.

At each visit, ask the questions listed in Figure 7.

Adjusting medication:

• If asthma is not controlled on the current treatment regimen, step up treatment. Generally, improvement should be seen within 1 month. But first review the patient’s medication technique, compliance, and avoidance of risk factors.

• If asthma is partly controlled, consider stepping up treatment, depending on whether more effective options are available, safety and cost of possible treatment options, and the patient’s satisfaction with the level of control achieved.

• If control is maintained for at least 3 months, step down with a gradual, stepwise reduction in treatment. The goal is to decrease treatment to the least medication necessary to maintain control.

Monitoring is still necessary even after control is achieved, as asthma is a variable disease; treatment has to be adjusted periodically in response to loss of control as indicated by worsening symptoms or the development of an exacerbation.
Figure 7. Questions for Monitoring Asthma Care

<table>
<thead>
<tr>
<th>IS THE ASTHMA MANAGEMENT PLAN MEETING EXPECTED GOALS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ask the patient:</strong></td>
</tr>
<tr>
<td>Has your asthma awakened you at night?</td>
</tr>
<tr>
<td>Have you needed more reliever medications than usual?</td>
</tr>
<tr>
<td>Have you needed any urgent medical care?</td>
</tr>
<tr>
<td>Has your peak flow been below your personal best?</td>
</tr>
<tr>
<td>Are you participating in your usual physical activities?</td>
</tr>
<tr>
<td><strong>Action to consider:</strong></td>
</tr>
<tr>
<td>Adjust medications and management plan as needed (step up or down).</td>
</tr>
<tr>
<td>But first, compliance should be assessed.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IS THE PATIENT USING INHALERS, SPACER, OR PEAK FLOW METERS CORRECTLY?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ask the patient:</strong></td>
</tr>
<tr>
<td>Please show me how you take your medicine.</td>
</tr>
<tr>
<td><strong>Action to consider:</strong></td>
</tr>
<tr>
<td>Demonstrate correct technique.</td>
</tr>
<tr>
<td>Have patient demonstrate back.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IS THE PATIENT TAKING THE MEDICATIONS AND AVOIDING RISK FACTORS ACCORDING TO THE ASTHMA MANAGEMENT PLAN?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ask the patient, for example:</strong></td>
</tr>
<tr>
<td>So that we may plan therapy, please tell me how often you actually take the medicine.</td>
</tr>
<tr>
<td>What problems have you had following the management plan or taking your medicine?</td>
</tr>
<tr>
<td>During the last month, have you ever stopped taking your medicine because you were feeling better?</td>
</tr>
<tr>
<td><strong>Action to consider:</strong></td>
</tr>
<tr>
<td>Adjust plan to be more practical.</td>
</tr>
<tr>
<td>Problem solve with the patient to overcome barriers to following the plan.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DOES THE PATIENT HAVE ANY CONCERNS?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ask the Patient:</strong></td>
</tr>
<tr>
<td>What concerns might you have about your asthma, medicines, or management plan?</td>
</tr>
<tr>
<td><strong>Action to consider:</strong></td>
</tr>
<tr>
<td>Provide additional education to relieve concerns and discussion to overcome barriers.</td>
</tr>
</tbody>
</table>
Component 4: Manage Exacerbations

Exacerbations of asthma (asthma attacks) are episodes of a progressive increase in shortness of breath, cough, wheezing, or chest tightness, or a combination of these symptoms.

**Do not underestimate the severity of an attack;** severe asthma attacks may be life threatening. Their treatment requires close supervision.

Patients at high risk of asthma-related death require closer attention and should be encouraged to seek urgent care early in the course of their exacerbations.

These patients include those:

- With a history of near-fatal asthma requiring intubation and mechanical ventilation
- Who have had a hospitalization or emergency visit for asthma within the past year
- Who are currently using or have recently stopped using oral glucocorticosteroids
- Who are not currently using inhaled glucocorticosteroids
- Who are over dependent on rapid-acting $\beta_2$-agonists, especially those who use more than one canister of salbutamol (or equivalent) monthly
- With a history of psychiatric disease or psychosocial problems, including the use of sedatives
- With a history of noncompliance with an asthma medication plan

**Patients should immediately seek medical care if:**

- The attack is severe (Figure 8):
  - The patient is breathless at rest, is hunched forward, talks in words rather than sentences (infant stops feeding), is agitated, drowsy, or confused, has bradycardia, or has a respiratory rate greater than 30 per minute
  - Wheeze is loud or absent
  - Pulse is greater than 120/min (greater than 160/min for infants)
  - PEF is less than 60 percent of predicted or personal best, even after initial treatment
  - The patient is exhausted

- The response to the initial bronchodilator treatment is not prompt and sustained for at least 3 hours
- There is no improvement within 2 to 6 hours after oral glucocorticosteroid treatment is started
- There is further deterioration
Mild attacks, defined by a reduction in peak flow of less than 20%, nocturnal awakening, and increased use of rapid-acting $\beta_2$-agonists, can usually be treated at home if the patient is prepared and has a personal asthma management plan that includes action steps.

Moderate attacks may require, and severe attacks usually require, care in a clinic or hospital.

Asthma attacks require **prompt treatment:**

- Inhaled rapid-acting $\beta_2$-agonists in adequate doses are essential. (Begin with 2 to 4 puffs every 20 minutes for the first hour; then mild exacerbations will require 2 to 4 puffs every 3 to 4 hours, and moderate exacerbations 6 to 10 puffs every 1 to 2 hours.)
- Oral glucocorticosteroids (0.5 to 1 mg of prednisolone/kg or equivalent during a 24-hour period) introduced early in the course of a moderate or severe attack help to reverse the inflammation and speed recovery.
- Oxygen is given at health centers or hospitals if the patient is hypoxemic (achieve $O_2$ saturation of 95%).
- Combination $\beta_2$-agonists/anticholinergic therapy is associated with lower hospitalization rates and greater improvement in PEF and FEV$_1$.
- Methylxanthines are not recommended if used in addition to high doses of inhaled $\beta_2$-agonists. However, theophylline can be used if inhaled $\beta_2$-agonists are not available. If the patient is already taking theophylline on a daily basis, serum concentration should be measured before adding short-acting theophylline.
- Patients with severe asthma exacerbations unresponsive to bronchodilators and systemic glucocorticosteroids, 2 grams of magnesium sulphate IV has been shown to reduce the need to hospitalizations.

Therapies not recommended for treating asthma attacks include:

- Sedatives (strictly avoid)
- Mucolytic drugs (may worsen cough)
- Chest physical therapy/physiotherapy (may increase patient discomfort)
- Hydration with large volumes of fluid for adults and older children (may be necessary for younger children and infants)
- Antibiotics (do not treat attacks but are indicated for patients who also have pneumonia or bacterial infection such as sinusitis)
- Epinephrine/adrenaline (may be indicated for acute treatment of anaphylaxis and angioedema but is not indicated for asthma attacks)
Monitor response to treatment:

Evaluate symptoms and, as much as possible, peak flow. In the hospital, also assess oxygen saturation; consider arterial blood gas measurement in patients with suspected hypoventilation, exhaustion, severe distress, or peak flow 30-50 percent predicted.

Follow up:

After the exacerbation is resolved, the factors that precipitated the exacerbation should be identified and strategies for their future avoidance implemented, and the patient’s medication plan reviewed.
### Figure 8. Severity of Asthma Exacerbations

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mild</th>
<th>Moderate</th>
<th>Severe</th>
<th>Respiratory arrest imminent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breathless</td>
<td>Walking</td>
<td>Talking</td>
<td>At rest</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Can lie down</td>
<td>Infant - softer, shorter cry; difficulty feeding</td>
<td>Infant stops feeding</td>
<td></td>
</tr>
<tr>
<td>Talks in</td>
<td>Sentences</td>
<td>Phrases</td>
<td>Words</td>
<td></td>
</tr>
<tr>
<td>Alertness</td>
<td>May be agitated</td>
<td>Usually agitated</td>
<td>Usually agitated</td>
<td>Drowsy or confused</td>
</tr>
<tr>
<td>Respiratory rate</td>
<td>Increased</td>
<td>Increased</td>
<td>Often &gt; 30/min</td>
<td></td>
</tr>
</tbody>
</table>

**Normal rates of breathing in awake children:**

<table>
<thead>
<tr>
<th>Age</th>
<th>Normal rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 2 months</td>
<td>&lt; 60/min</td>
</tr>
<tr>
<td>2 - 12 months</td>
<td>&lt; 50 /min</td>
</tr>
<tr>
<td>1 - 5 years</td>
<td>&lt; 40 /min</td>
</tr>
<tr>
<td>6 - 8 years</td>
<td>&lt; 30 /min</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Accessory muscles and suprasternal retractions</th>
<th>Usually not</th>
<th>Usually</th>
<th>Usually</th>
<th>Paradoxical thoraco-abdominal movement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheeze</td>
<td>Moderate, often only and expiratory</td>
<td>Loud</td>
<td>Usually loud</td>
<td>Absence of wheeze</td>
</tr>
<tr>
<td>Pulse/min.</td>
<td>&lt; 100</td>
<td>100 - 200</td>
<td>&gt; 120</td>
<td>Bradycardia</td>
</tr>
</tbody>
</table>

**Guide to limits of normal pulse rate in children:**

<table>
<thead>
<tr>
<th>Pulsus paradoxus</th>
<th>Infants</th>
<th>Preschool</th>
<th>School age</th>
</tr>
</thead>
<tbody>
<tr>
<td>May be present</td>
<td>10 - 25 mm Hg</td>
<td>20 - 40 mm Hg</td>
<td>25 mm Hg (adult)</td>
</tr>
<tr>
<td>Absent</td>
<td>&lt; 10 mm Hg</td>
<td>&lt; 160/min</td>
<td>&lt; 110/min</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PEF after initial bronchodilator % predicted or % personal best</th>
<th>Over 80%</th>
<th>Approx. 60-80%</th>
<th>&lt; 60% predicted or personal best (&lt; 100 L/min adults) or response lasts &lt; 2 hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>PaO₂ (on air)†</td>
<td>Normal</td>
<td>&gt; 60 mm Hg</td>
<td>&lt; 60 mm Hg Possible cyanosis</td>
</tr>
<tr>
<td>and/or paCO₂†</td>
<td>&lt; 45 mm Hg</td>
<td>&lt; 45 mm Hg</td>
<td>&gt; 45 mm Hg; Possible respiratory failure (see text)</td>
</tr>
<tr>
<td>So₂, % (on air)†</td>
<td>&gt; 95%</td>
<td>91 - 95%</td>
<td>&lt; 90%</td>
</tr>
</tbody>
</table>

Hypercapnia (hyperventilation) develops more readily in young children than adults and adolescents

*Note: The presence of several parameters, but no necessarily all, indicates the general classification of the exacerbation.
†Note: Kilopascals are also used internationally, conversion would be appropriate in this regard.
SPECIAL CONSIDERATIONS IN MANAGING ASTHMA

- **Pregnancy.** During pregnancy the severity of asthma often changes, and patients may require close follow-up and adjustment of medications. Pregnant patients with asthma should be advised that the greater risk to their baby lies with poorly controlled asthma, and the safety of most modern asthma treatments should be stressed. Acute exacerbations should be treated aggressively to avoid fetal hypoxia.

- **Obesity.** Management of asthma in the obese should be the same as patients with normal weight. Weight loss in the obese patient improves asthma control, lung function and reduces medication needs.

- **Surgery.** Airway hyperresponsiveness, airflow limitation, and mucus hypersecretion predispose patients with asthma to intraoperative and postoperative respiratory complications, particularly with thoracic and upper abdominal surgeries. Lung function should be evaluated several days prior to surgery, and a brief course of glucocorticosteroids prescribed if FEV₁ is less than 80% of the patient’s personal best.

- **Rhinitis, Sinusitis, and Nasal Polyps.** Rhinitis and asthma often coexist in the same patient, and treatment of rhinitis may improve asthma symptoms. Both acute and chronic sinusitis can worsen asthma, and should be treated. Nasal polyps are associated with asthma and rhinitis, often with aspirin sensitivity and most frequently in adult patients. They are normally quite responsive to topical glucocorticosteroids.

- **Occupational asthma.** Pharmacologic therapy for occupational asthma is identical to therapy for other forms of asthma, but is not a substitute for adequate avoidance of the relevant exposure. Consultation with a specialist in asthma management or occupational medicine is advisable.

- **Respiratory infections.** Respiratory infections provoke wheezing and increased asthma symptoms in many patients. Treatment of an infectious exacerbation follows the same principles as treatment of other exacerbations.

- **Gastroesophageal reflux.** Gastroesophageal reflux is more common in patients with asthma compared to the general population. However, treatment with proton pump inhibitors, H₂ antagonists or surgery fail to improve asthma control.

- **Aspirin-induced asthma.** Up to 28 percent of adults with asthma, but rarely children, suffer from asthma exacerbations in response to aspirin and other nonsteroidal anti-inflammatory drugs. The diagnosis can only be confirmed by aspirin challenge, which must be conducted in a facility with cardiopulmonary resuscitation capabilities. Complete avoidance of the drugs that cause symptoms is the standard management.

- **Anaphylaxis.** Anaphylaxis is a potentially life-threatening condition that can both mimic and complicate severe asthma. Prompt treatment is crucial and includes oxygen, intramuscular epinephrine, injectable antihistamine, intravenous hydrocortisone, and intravenous fluid.
### Appendix A: Glossary of Asthma Medications - Controllers

<table>
<thead>
<tr>
<th>Name and Also Known As</th>
<th>Usual Doses</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Glucocorticosteroids</strong></td>
<td><strong>Inhaled:</strong> Beginning dose dependent on asthma control then titrated down over 2-3 months to lowest effect dose once control is achieved.</td>
<td><strong>Inhaled:</strong> High daily doses may be associated with skin thinning and bruises, and rarely adrenal suppression. Local side effects are hoarseness and oropharyngeal candidiasis. Low to medium doses have produced minor growth delay or suppression (av. 1 cm) in children. Attainment of predicted adult height does not appear to be affected.</td>
<td><strong>Inhaled:</strong> Inhaled. Potential but small risk of side effects is well balanced by efficacy. Valved holding chambers with MDIs and mouth washing with DPIs after inhalation decrease oral candidiasis. Preparations note equivalent on per puff or µg basis.</td>
</tr>
<tr>
<td>Adrenocorticoids</td>
<td>Corticosteroids</td>
<td>Glucocorticoids</td>
<td></td>
</tr>
<tr>
<td><strong>Inhaled (ICS):</strong></td>
<td><strong>Tablets or syrups:</strong> For daily control use lowest effective dose 5-40 mg of prednisone equivalent in a.m. or qid. For acute attacks 40-60 mg daily in 1 or 2 divided doses for adults or 1-2 mg/kg daily in children.</td>
<td></td>
<td><strong>Tablets or syrups:</strong> Long term use: alternate day a.m. dosing produces less toxicity. Short term: 3-10 day &quot;bursts&quot; are effective for gaining prompt control.</td>
</tr>
<tr>
<td>Beclomethasone</td>
<td>Budesonide</td>
<td>Ciclesonide</td>
<td>Flunisolide</td>
</tr>
<tr>
<td><strong>Tablets or syrups:</strong></td>
<td>hydrocortisone</td>
<td>methylprednisolone</td>
<td>prednisolone</td>
</tr>
<tr>
<td><strong>Sodium cromoglycate</strong></td>
<td><strong>MDI 2 mg or 5 mg 2-4 inhalations 3-4 times daily. Nebulizer 20 mg 3-4 times daily.</strong></td>
<td>Minimal side effects. Cough may occur upon inhalation.</td>
<td>May take 4-6 weeks to determine maximum effects. Frequent daily dosing required.</td>
</tr>
<tr>
<td>cromolyn</td>
<td>cromones</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Nedocromil</strong></td>
<td><strong>MDI 2 mg/puff 2-4 inhalations 2-4 times daily.</strong></td>
<td>Cough may occur upon inhalation.</td>
<td>Some patients unable to tolerate the taste.</td>
</tr>
<tr>
<td>cromones</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Long-acting β&lt;sub&gt;2&lt;/sub&gt;-agonists</strong></td>
<td><strong>Inhaled:</strong> DPI - F: 1 inhalation (12 µg) bid. DPI - Sm: 1 inhalation (50 µg) bid. <strong>Tablets:</strong> S: 4 mg q 12h. T: 10 mg q 12h. <strong>Starting dose does 10 mg/kg/day with usual 800 mg maximum in 1-2 divided doses.</strong></td>
<td>Inhaled: Inhaled. Fewer, and less significant, side effects than tablets. Have been associated with an increased risk of severe exacerbations and asthma deaths when added to usual therapy.</td>
<td>Inhaled: Salmeterol NOT to be used to treat acute attacks. Should not use as mono therapy for controller therapy. Always use as adjunct to ICS therapy. Formoterol has onset similar to salbutamol and has been used as needed for acute symptoms.</td>
</tr>
<tr>
<td>beta-agonists</td>
<td>sympathomimetics</td>
<td>LABAs</td>
<td></td>
</tr>
<tr>
<td><strong>Inhaled:</strong></td>
<td>Formoterol (F)</td>
<td>Salmeterol (Sm)</td>
<td></td>
</tr>
<tr>
<td><strong>Sustained-release Tablets:</strong></td>
<td>Salbutamol (S)</td>
<td>Terbutaline (T)</td>
<td>Aminophylline</td>
</tr>
<tr>
<td><strong>Inhaled:</strong> Formoterol has onset similar to salbutamol and has been used as needed for acute symptoms.</td>
<td></td>
<td></td>
<td>Theophylline level monitoring is often required. Absorption and metabolism may be affected by many factors, including febrile illness.</td>
</tr>
</tbody>
</table>
### Appendix A: Glossary of Asthma Medications - Controllers (continued…)

<table>
<thead>
<tr>
<th>Name and Also Known As</th>
<th>Usual Doses</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antileukotrienes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukotriene modifiers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Montelukast (M)</td>
<td>Adults: M 10 mg qhs; P 450 mg bid; Z 20 mg bid; Z 600 mg qid.</td>
<td>No specific adverse effects to date at recommended doses. Elevation of liver enzymes with Zafirlukast and Zileuton and limited case reports of reversible hepatitis and hperbilirubinemia with Zileuton and hepatic failure with afirlukast</td>
<td>Antileukotrienes are most effective for patients with mild persistent asthma. They provide additive benefit when added to ICSs, though not as effective as inhaled long-acting β₂-agonists.</td>
</tr>
<tr>
<td>Pranlukast (P)</td>
<td>Children: M 5 mg qhs (6 - 14 y); M 4 mg qhs (2-5 y); Z 10 mg bid (7 - 11 y).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zafirlukast (Z)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zileuton (Zi)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Appendix B: Combination Medications for Asthma

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Inhaler Devices</th>
<th>Doses Available (µg)</th>
<th>Inhalations/day</th>
<th>Therapeutic Use</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluticasone propionate/ salmeterol</td>
<td>DPI</td>
<td>100/50¹, 250/50, 500/50</td>
<td>1 inhalation x 2</td>
<td>Maintenance</td>
</tr>
<tr>
<td></td>
<td>pMDI (Suspension)</td>
<td>50/25, 125/25, 250/25</td>
<td>2 inhalations x 2</td>
<td>Maintenance</td>
</tr>
<tr>
<td>Budesonide/ formoterol</td>
<td>DPI</td>
<td>80/4.5², 160/4.5, 320/9.0</td>
<td>1-2 inhalations x 2</td>
<td>Maintenance and Relief</td>
</tr>
<tr>
<td></td>
<td>pMDI (Suspension)</td>
<td>100/6, 200/6</td>
<td>2 inhalations x 2</td>
<td>Maintenance</td>
</tr>
<tr>
<td>Beclomethasone/ formoterol</td>
<td>pMDI (Solution)</td>
<td>100/6³</td>
<td>1-2 inhalations x 2</td>
<td>Maintenance</td>
</tr>
<tr>
<td>Mometasone/ formoterol</td>
<td>pMDI</td>
<td>100/5, 200/5</td>
<td>2 inhalations x 2</td>
<td>Maintenance</td>
</tr>
</tbody>
</table>

ICS = inhaled corticosteroid; LABA = long-acting β₂-agonist; pMDI = pressurized metered dose inhaler; DPI = dry powder inhaler.

New formulations will be reviewed for inclusion in the table as they are approved. Such medications may be brought to the attention of the GINA Science Committee.

¹Refers to metered dose. For additional information about dosages and products available in specific countries, please consult www.gsk.com to find a link to your country website or contact your local company representatives for products approved for use in your country.

²Refers to delivered dose. For additional information about dosages and products available in specific countries, please consult www.astrazeneca.com to find a link to your country website or contact your local company representatives for products approved for use in your country.

³Refers to metered dose. For additional information about dosages and products available in specific countries, please consult www.chiesigroup.com to find a link to your country website or contact your local company representatives for products approved for use in your country.
<table>
<thead>
<tr>
<th>Name and Also Known As</th>
<th>Usual Doses</th>
<th>Side Effects</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Short-acting ( \beta_2 ) -agonists</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adrenergics</td>
<td>Differences in potency exist but all products are essentially comparable on a per puff basis. For pre-symptomatic use and pretreatment before exercise 2 puffs MDI or 1 inhalation DPI. For asthma attacks 4-8 puffs q2-4h, may administer q20min x 3 with medical supervision or the equivalent of 5mg salbutamol by nebulizer.</td>
<td>Inhaled: tachycardia, skeletal muscle tremor, headache, and irritability. At very high dose hyperglycemia, hypokalemia.</td>
<td>Drug of choice for acute bronchospasm. Inhaled route has faster onset and is more effective than tablet or syrup. Increasing dose, lack of expected effect, or use of &gt; 1 canister a month indicate poor asthma control; adjust long-term therapy accordingly. Use of ( \geq 2 ) canisters per month is associated with an increased risk of a severe, life-threatening asthma attack.</td>
</tr>
<tr>
<td>( \beta_2 )-stimulants</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptomimetics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Albuterol/salbutamol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fenoterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levalbuterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metaproterenol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pirbuterol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Terbutaline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anticholinergics</strong></td>
<td>1-8 MDI 4-6 puffs q6h or q20 min in the emergency department. Nebulizer 500 ( \mu )g q20min x 3 then q2-4hrs for adults and 250-500 ( \mu )g for children.</td>
<td>Minimal mouth dryness or bad taste in the mouth.</td>
<td>May provide additive effects to ( \beta_2 )-agonists but has slower onset of action. Is an alternative for patients with intolerance to ( \beta_2 )-agonists.</td>
</tr>
<tr>
<td>Ipratropium bromide (IB)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxitropium bromide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short-acting theophylline</strong></td>
<td>7 mg/kg loading dose over 20 min followed by 0.4mg/kg/hr continuous infusion.</td>
<td>Nausea, vomiting, headache. At higher serum concentrations: seizures, tachycardia, and arrhythmias.</td>
<td>Theophylline level monitoring is required. Obtain serum levels 12 and 24 hours into infusion. Maintain between 10-15 ( \mu )g/mL.</td>
</tr>
<tr>
<td>Aminophylline</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Epinephrine/adrenaline injection</strong></td>
<td>1:1000 solution (1mg/mL) 0.01mg/kg up to 0.3-0.5 mg, can give q20min x 3.</td>
<td>Similar, but more significant effects than selective ( \beta_2 )-agonist. In addition: hypertension, vomiting in children and hallucinations</td>
<td>In general, not recommended for treating asthma attacks if selective ( \beta_2 )-agonists are available.</td>
</tr>
</tbody>
</table>
The Global Initiative for Asthma is supported by unrestricted education grants from:

Almirall
AstraZeneca
Boehringer Ingelheim
Chiesi Group
CIPLA
GlaxoSmithKline
Merck Sharp & Dohme
Novartis
Quintiles
Takeda

Visit the GINA website at www.ginasthma.org

© 2012 Global Initiative for Asthma